News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 03:39:00 2024-04-25 pm EDT			5-day change	1st Jan Change
893.8 ^USD	-1.41%		-0.08%	+1.70%

02:05pm	Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences	DJ
01:00pm	Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences	08:05am	DJ
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases	07:00am	GL
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases	07:00am	CI
Sanofi Q1 profit slips on generic competition, forex effects	01:30am	RE
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO	Apr. 24	GL
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating	Apr. 24	MT
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	Apr. 23	MT
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)	Apr. 22	GL
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors	Apr. 17	BU
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating	Apr. 17	MT
The market is pinning its hopes on earnings reports	Apr. 17
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Regeneron to defend against DOJ complaint on drug-price manipulation	Apr. 15	RE
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation	Apr. 15	RE
Regeneron Pharmaceuticals : Statement on Department of Justice Filing Related to EYLEA® (aflibercept) Injection 2 mg	Apr. 15	PU
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	Apr. 15	MT
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Summary

Filters